AUROPHARMA.NSAUROPHARMA.NSNSE
Loading
Year-over-year net income growth rate
3Y CAGR
-28.6%/yr
vs +189.1%/yr prior
5Y CAGR
-51.3%/yr
Recent acceleration
Acceleration
-217.7pp
Decelerating
Percentile
P69
Within normal range
vs 5Y Ago
0x
Contraction
Streak
2 qtr
Consecutive growthStable
| Period | Value |
|---|---|
| Q4 2025 | 7.29% |
| Q3 2025 | 2.87% |
| Q2 2025 | -8.71% |
| Q1 2025 | 6.82% |
| Q4 2024 | 3.48% |
| Q3 2024 | -11.08% |
| Q2 2024 | 1.15% |
| Q1 2024 | -2.94% |
| Q4 2023 | 23.65% |
| Q3 2023 | 32.66% |
| Q2 2023 | 12.74% |
| Q1 2023 | 3.06% |
| Q4 2022 | 19.98% |
| Q3 2022 | -21.34% |
| Q2 2022 | -9.70% |
| Q1 2022 | -4.67% |
| Q4 2021 | -13.24% |
| Q3 2021 | -9.48% |
| Q2 2021 | -3.94% |
| Q1 2021 | -72.80% |
| Q4 2020 | 265.46% |
| Q3 2020 | 3.29% |
| Q2 2020 | -9.66% |
| Q1 2020 | 22.48% |
| Q4 2019 | 10.25% |
| Q3 2019 | 0.63% |
| Q2 2019 | 8.61% |
| Q1 2019 | -17.80% |
| Q4 2018 | 16.48% |
| Q3 2018 | 34.19% |
| Q2 2018 | -13.78% |
| Q1 2018 | -11.18% |
| Q4 2017 | -23.83% |
| Q3 2017 | 50.65% |
| Q2 2017 | -2.62% |
| Q1 2017 | -7.97% |
| Q4 2016 | -4.47% |
| Q3 2016 | 3.54% |
| Q2 2016 | -3.46% |
| Q1 2016 | 13.27% |